BioSenic S.A. Puts Phase IIb Allob Trial on Hold

BioSenic announced the decision to suspend its interventional trial on fracture healing, using the ex-Bone-Therapeutics lead product, ALLOB. This decision follows negative results obtained for the primary endpoint in the exploratory Phase IIb trial, which focused on safety and treatment timing efficacy.